#ID(s) interactor A	ID(s) interactor B	Alt. ID(s) interactor A	Alt. ID(s) interactor B	Alias(es) interactor A	Alias(es) interactor B	Interaction detection method(s)	Publication 1st author(s)	Publication Identifier(s)	Taxid interactor A	Taxid interactor B	Interaction type(s)	Source database(s)	Interaction identifier(s)	Confidence value(s)	Experimental role(s) interactor A	Experimental role(s) interactor B	Biological role(s) interactor A	Biological role(s) interactor B	Properties interactor A	Properties interactor B	Type(s) interactor A	Type(s) interactor B	HostOrganism(s)	Expansion method(s)	Dataset name(s)	Annotation(s) interactor A	Annotation(s) interactor B	Parameter(s) interactor A	Parameter(s) interactor B	Parameter(s) interaction
uniprotkb:P00734|intact:DGI-5390	chebi:"CHEBI:45906"|drugbank:DB04786|intact:DGI-173729	-	intact:Bayer 205(drug brand name)|intact:SVR(drug brand name)|intact:Sodium suramin(drug brand name)|intact:Suramin sodium(drug brand name)|intact:Suramine(drug brand name)|intact:Suramine sodium(drug brand name)|intact:Suramin(commercial name)|intact:Germanin(drug brand name)|intact:Antrypol(drug brand name)|intact:Fourneau(drug brand name)|intact:Farma(drug brand name)|intact:Belganyl(drug brand name)|intact:Moranyl(drug brand name)|intact:Naganil(drug brand name)|intact:Naganin(drug brand name)|intact:Naganine(drug brand name)|intact:Naganol(drug brand name)|intact:Naphuride(drug brand name)	uniprotkb:F2	-	MI:0045(experimental interac)	-	pubmed:18048412	taxid:9606(human)	taxid:-3(unknown)	MI:0407(direct interaction)	psi-mi:"MI:1002"	intact:DGI-173781	-	MI:1095(drug target)	MI:1094(drug)	MI:0499(unspecified role)	MI:0499(unspecified role)	-	-	MI:0326(protein)	MI:0328(small molecule)	taxid:-3(unknown)	-	DrugBank - a knowledgebase for drugs, drug actions and drug targets.	-	biotech prep:"A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®."|drug type:Small Molecule; Approved|drug category:Antinematodal Agents; Antineoplastic Agents; Trypanocidal Agents|disease indication:For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms.|mechanism of action:"The mechanism is unknown, but the trypanocidal activity may be due to the inhibition of enzymes involved with the oxidation of reduced nicotinamide-adenine dinucleotide (NADH), which functions as a co-enzyme in many cellular reactions, such as respiration and glycolysis, in the trypanosome parasite. Suramin's action in the treatment of onchocerciasis is macrofilaricidal and partially microfilaricidal."|comment:"drug absorption (MI:2045): Poorly absorbed from the gastrointestinal tract."|comment:"plasma protein binding (MI:2047):Approximately 99.7%"|drug metabolism:Little or no metabolism|comment:"elimination half life (MI:2049): Approximately 36 to 60 days"|dosage form:Injection, powder, for solution Intravenous|organisms affected:Yeast, Molds, Trypanosomes|inchi id:"InChI=1/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)/f/h52-57,63,66,69,72,75,78H"|comment:"average molecular weight (MI:2155): 1297.2797"|comment:"monoisotopic molecular weight (MI:2156): 1296.0469"|comment:"predicted h2o solubility (MI:2158): 8.72e-03 mg/mL [ALOGPS]"	-	-	-
uniprotkb:P41231|intact:DGI-173784	chebi:"CHEBI:45906"|drugbank:DB04786|intact:DGI-173729	-	intact:Bayer 205(drug brand name)|intact:SVR(drug brand name)|intact:Sodium suramin(drug brand name)|intact:Suramin sodium(drug brand name)|intact:Suramine(drug brand name)|intact:Suramine sodium(drug brand name)|intact:Suramin(commercial name)|intact:Germanin(drug brand name)|intact:Antrypol(drug brand name)|intact:Fourneau(drug brand name)|intact:Farma(drug brand name)|intact:Belganyl(drug brand name)|intact:Moranyl(drug brand name)|intact:Naganil(drug brand name)|intact:Naganin(drug brand name)|intact:Naganine(drug brand name)|intact:Naganol(drug brand name)|intact:Naphuride(drug brand name)	uniprotkb:P2RY2	-	MI:0045(experimental interac)	-	pubmed:18048412	taxid:9606(human)	taxid:-3(unknown)	MI:0407(direct interaction)	psi-mi:"MI:1002"	intact:DGI-173788	-	MI:1095(drug target)	MI:1094(drug)	MI:0499(unspecified role)	MI:0499(unspecified role)	-	-	MI:0326(protein)	MI:0328(small molecule)	taxid:-3(unknown)	-	DrugBank - a knowledgebase for drugs, drug actions and drug targets.	-	biotech prep:"A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®."|drug type:Small Molecule; Approved|drug category:Antinematodal Agents; Antineoplastic Agents; Trypanocidal Agents|disease indication:For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms.|mechanism of action:"The mechanism is unknown, but the trypanocidal activity may be due to the inhibition of enzymes involved with the oxidation of reduced nicotinamide-adenine dinucleotide (NADH), which functions as a co-enzyme in many cellular reactions, such as respiration and glycolysis, in the trypanosome parasite. Suramin's action in the treatment of onchocerciasis is macrofilaricidal and partially microfilaricidal."|comment:"drug absorption (MI:2045): Poorly absorbed from the gastrointestinal tract."|comment:"plasma protein binding (MI:2047):Approximately 99.7%"|drug metabolism:Little or no metabolism|comment:"elimination half life (MI:2049): Approximately 36 to 60 days"|dosage form:Injection, powder, for solution Intravenous|organisms affected:Yeast, Molds, Trypanosomes|inchi id:"InChI=1/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)/f/h52-57,63,66,69,72,75,78H"|comment:"average molecular weight (MI:2155): 1297.2797"|comment:"monoisotopic molecular weight (MI:2156): 1296.0469"|comment:"predicted h2o solubility (MI:2158): 8.72e-03 mg/mL [ALOGPS]"	-	-	-
